← FDA DRUG APPROVALS

FDA ANDA · ANDA218036

LITHIUM

Sponsor: RUBICON RESEARCH

APPLICATION
ANDA218036
TYPE
ANDA
ORIGINAL APPROVAL
2023-08-14
LATEST ACTION
2023-08-14
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Prescription

Products

LITHIUM CITRATEPrescription
LITHIUM CITRATE EQ 300MG CARBONATE/5ML · SYRUP · ORAL

Approval history

2023-08-14UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →